STOCK TITAN

[Form 4] Immix Biopharma, Inc. Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Carey Ng, Director of Immix Biopharma (IMMX), reported significant insider trading activity on June 20, 2025. The key transactions include:

  • Acquisition of a stock option grant for 33,000 shares with an exercise price of $2.24, expiring June 20, 2035
  • The options will vest in 12 equal monthly installments following the grant date, contingent on continued Board service
  • Current holdings include 20,000 shares held directly and 1,025,221 shares held indirectly through Mesa Verde Venture Partners III, LP

As Managing Director of Mesa Verde Venture Partners III, LP, Ng has voting and dispositive power over the fund's holdings but disclaims beneficial ownership except for his pecuniary interest. The transaction was executed under a valid Power of Attorney filed previously with the SEC.

Carey Ng, Direttore di Immix Biopharma (IMMX), ha riportato un'attività significativa di trading interno il 20 giugno 2025. Le operazioni principali includono:

  • Acquisizione di una concessione di opzioni su azioni per 33.000 azioni con un prezzo di esercizio di 2,24$, con scadenza il 20 giugno 2035
  • Le opzioni matureranno in 12 rate mensili uguali a partire dalla data di concessione, subordinatamente al proseguimento del servizio nel Consiglio
  • Le partecipazioni attuali comprendono 20.000 azioni detenute direttamente e 1.025.221 azioni detenute indirettamente tramite Mesa Verde Venture Partners III, LP

In qualità di Managing Director di Mesa Verde Venture Partners III, LP, Ng detiene il potere di voto e decisionale sulle partecipazioni del fondo, ma nega la proprietà beneficiaria tranne che per il suo interesse patrimoniale. La transazione è stata eseguita sotto una valida procura precedentemente depositata presso la SEC.

Carey Ng, Director de Immix Biopharma (IMMX), reportó una actividad significativa de operaciones internas el 20 de junio de 2025. Las transacciones clave incluyen:

  • Adquisición de una concesión de opciones sobre acciones por 33,000 acciones con un precio de ejercicio de $2.24, que expira el 20 de junio de 2035
  • Las opciones se consolidarán en 12 cuotas mensuales iguales a partir de la fecha de concesión, condicionadas a la continuidad en el servicio en la Junta
  • Las tenencias actuales incluyen 20,000 acciones en propiedad directa y 1,025,221 acciones en propiedad indirecta a través de Mesa Verde Venture Partners III, LP

Como Director General de Mesa Verde Venture Partners III, LP, Ng tiene poder de voto y disposición sobre las tenencias del fondo, pero renuncia a la propiedad beneficiaria excepto por su interés pecuniario. La transacción se ejecutó bajo un Poder Notarial válido presentado previamente ante la SEC.

케리 응(Carey Ng), Immix Biopharma(IMMX) 이사, 2025년 6월 20일에 중요한 내부자 거래 활동을 보고했습니다. 주요 거래 내용은 다음과 같습니다:

  • 행사가격 $2.24, 만료일 2035년 6월 20일인 주식 매수선택권 부여 33,000주 취득
  • 옵션은 부여일 이후 12개월간 매월 동일 비율로 권리 확정, 이사회 지속 근무 조건부
  • 현재 직접 보유 주식 20,000주와 Mesa Verde Venture Partners III, LP를 통한 간접 보유 주식 1,025,221주 포함

Mesa Verde Venture Partners III, LP의 전무이사로서 Ng는 펀드 보유 주식에 대한 의결권과 처분 권한을 가지고 있으나, 금전적 이해관계를 제외한 실질 소유권은 부인합니다. 본 거래는 SEC에 사전 제출된 유효한 위임장을 통해 실행되었습니다.

Carey Ng, Directeur d'Immix Biopharma (IMMX), a signalé une activité importante d'opérations d'initiés le 20 juin 2025. Les transactions clés comprennent :

  • Acquisition d'une attribution d'options d'achat d'actions pour 33 000 actions avec un prix d'exercice de 2,24 $, expirant le 20 juin 2035
  • Les options seront acquises par 12 versements mensuels égaux à partir de la date d'attribution, sous réserve de la poursuite du service au Conseil
  • Les avoirs actuels comprennent 20 000 actions détenues directement et 1 025 221 actions détenues indirectement via Mesa Verde Venture Partners III, LP

En tant que Directeur Général de Mesa Verde Venture Partners III, LP, Ng détient le pouvoir de vote et de disposition sur les avoirs du fonds, mais décline la propriété bénéficiaire sauf pour son intérêt pécuniaire. La transaction a été réalisée sous une procuration valide déposée précédemment auprès de la SEC.

Carey Ng, Direktor von Immix Biopharma (IMMX), meldete am 20. Juni 2025 eine bedeutende Insiderhandelstätigkeit. Die wichtigsten Transaktionen umfassen:

  • Erwerb einer Aktienoptionszuteilung über 33.000 Aktien mit einem Ausübungspreis von 2,24 USD, gültig bis zum 20. Juni 2035
  • Die Optionen werden in 12 gleichen monatlichen Raten nach dem Zuteilungsdatum fällig, vorausgesetzt, die Vorstandstätigkeit wird fortgesetzt
  • Derzeitiger Bestand umfasst 20.000 direkt gehaltene Aktien sowie 1.025.221 indirekt über Mesa Verde Venture Partners III, LP gehaltene Aktien

Als Geschäftsführer von Mesa Verde Venture Partners III, LP hat Ng Stimm- und Verfügungsrecht über die Fondsbestände, bestreitet jedoch das wirtschaftliche Eigentum mit Ausnahme seines finanziellen Interesses. Die Transaktion wurde unter einer zuvor bei der SEC eingereichten gültigen Vollmacht durchgeführt.

Positive
  • None.
Negative
  • None.

Carey Ng, Direttore di Immix Biopharma (IMMX), ha riportato un'attività significativa di trading interno il 20 giugno 2025. Le operazioni principali includono:

  • Acquisizione di una concessione di opzioni su azioni per 33.000 azioni con un prezzo di esercizio di 2,24$, con scadenza il 20 giugno 2035
  • Le opzioni matureranno in 12 rate mensili uguali a partire dalla data di concessione, subordinatamente al proseguimento del servizio nel Consiglio
  • Le partecipazioni attuali comprendono 20.000 azioni detenute direttamente e 1.025.221 azioni detenute indirettamente tramite Mesa Verde Venture Partners III, LP

In qualità di Managing Director di Mesa Verde Venture Partners III, LP, Ng detiene il potere di voto e decisionale sulle partecipazioni del fondo, ma nega la proprietà beneficiaria tranne che per il suo interesse patrimoniale. La transazione è stata eseguita sotto una valida procura precedentemente depositata presso la SEC.

Carey Ng, Director de Immix Biopharma (IMMX), reportó una actividad significativa de operaciones internas el 20 de junio de 2025. Las transacciones clave incluyen:

  • Adquisición de una concesión de opciones sobre acciones por 33,000 acciones con un precio de ejercicio de $2.24, que expira el 20 de junio de 2035
  • Las opciones se consolidarán en 12 cuotas mensuales iguales a partir de la fecha de concesión, condicionadas a la continuidad en el servicio en la Junta
  • Las tenencias actuales incluyen 20,000 acciones en propiedad directa y 1,025,221 acciones en propiedad indirecta a través de Mesa Verde Venture Partners III, LP

Como Director General de Mesa Verde Venture Partners III, LP, Ng tiene poder de voto y disposición sobre las tenencias del fondo, pero renuncia a la propiedad beneficiaria excepto por su interés pecuniario. La transacción se ejecutó bajo un Poder Notarial válido presentado previamente ante la SEC.

케리 응(Carey Ng), Immix Biopharma(IMMX) 이사, 2025년 6월 20일에 중요한 내부자 거래 활동을 보고했습니다. 주요 거래 내용은 다음과 같습니다:

  • 행사가격 $2.24, 만료일 2035년 6월 20일인 주식 매수선택권 부여 33,000주 취득
  • 옵션은 부여일 이후 12개월간 매월 동일 비율로 권리 확정, 이사회 지속 근무 조건부
  • 현재 직접 보유 주식 20,000주와 Mesa Verde Venture Partners III, LP를 통한 간접 보유 주식 1,025,221주 포함

Mesa Verde Venture Partners III, LP의 전무이사로서 Ng는 펀드 보유 주식에 대한 의결권과 처분 권한을 가지고 있으나, 금전적 이해관계를 제외한 실질 소유권은 부인합니다. 본 거래는 SEC에 사전 제출된 유효한 위임장을 통해 실행되었습니다.

Carey Ng, Directeur d'Immix Biopharma (IMMX), a signalé une activité importante d'opérations d'initiés le 20 juin 2025. Les transactions clés comprennent :

  • Acquisition d'une attribution d'options d'achat d'actions pour 33 000 actions avec un prix d'exercice de 2,24 $, expirant le 20 juin 2035
  • Les options seront acquises par 12 versements mensuels égaux à partir de la date d'attribution, sous réserve de la poursuite du service au Conseil
  • Les avoirs actuels comprennent 20 000 actions détenues directement et 1 025 221 actions détenues indirectement via Mesa Verde Venture Partners III, LP

En tant que Directeur Général de Mesa Verde Venture Partners III, LP, Ng détient le pouvoir de vote et de disposition sur les avoirs du fonds, mais décline la propriété bénéficiaire sauf pour son intérêt pécuniaire. La transaction a été réalisée sous une procuration valide déposée précédemment auprès de la SEC.

Carey Ng, Direktor von Immix Biopharma (IMMX), meldete am 20. Juni 2025 eine bedeutende Insiderhandelstätigkeit. Die wichtigsten Transaktionen umfassen:

  • Erwerb einer Aktienoptionszuteilung über 33.000 Aktien mit einem Ausübungspreis von 2,24 USD, gültig bis zum 20. Juni 2035
  • Die Optionen werden in 12 gleichen monatlichen Raten nach dem Zuteilungsdatum fällig, vorausgesetzt, die Vorstandstätigkeit wird fortgesetzt
  • Derzeitiger Bestand umfasst 20.000 direkt gehaltene Aktien sowie 1.025.221 indirekt über Mesa Verde Venture Partners III, LP gehaltene Aktien

Als Geschäftsführer von Mesa Verde Venture Partners III, LP hat Ng Stimm- und Verfügungsrecht über die Fondsbestände, bestreitet jedoch das wirtschaftliche Eigentum mit Ausnahme seines finanziellen Interesses. Die Transaktion wurde unter einer zuvor bei der SEC eingereichten gültigen Vollmacht durchgeführt.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Ng Carey

(Last) (First) (Middle)
C/O IMMIX BIOPHARMA, INC.
11400 WEST OLYMPIC BLVD., SUITE 200

(Street)
LOS ANGELES CA 90064

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Immix Biopharma, Inc. [ IMMX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/20/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 20,000 D
Common Stock 1,025,221 I See footnote(1)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $2.24 06/20/2025 A 33,000 (2) 06/20/2035 Common Stock 33,000 $0.00 33,000 D
Explanation of Responses:
1. Carey Ng is the Managing Director of Mesa Verde Venture Partners III, LP ("Mesa Verde") and in such capacity has the right to vote and dispose of the securities held by such entity. Mr. Ng disclaims beneficial ownership of the securities held by Mesa Verde, except to the extent of his pecuniary interest therein.
2. The Stock Option will vest in twelve (12) equal monthly installments following the date of grant, subject to the Reporting Person's continued service on the Board of Directors.
Remarks:
See Power of Attorney filed as Exhibit 24.1 to the Form 3 filed by the Reporting Person on December 15, 2021.
/s/ Ilya Rachman as Attorney-In-Fact for Carey Ng 06/23/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many stock options did IMMX director Carey Ng receive on June 20, 2025?

Carey Ng received 33,000 stock options (right to buy) of IMMX on June 20, 2025, with an exercise price of $2.24 per share.

What is the vesting schedule for Carey Ng's IMMX stock options granted in June 2025?

The stock options will vest in twelve (12) equal monthly installments following the date of grant (June 20, 2025), subject to Ng's continued service on the Board of Directors.

How many shares of IMMX common stock does Carey Ng directly own?

Carey Ng directly owns 20,000 shares of IMMX common stock, as reported in Table I of the Form 4 filing.

What is Carey Ng's indirect ownership position in IMMX through Mesa Verde Venture Partners?

Carey Ng has indirect beneficial ownership of 1,025,221 shares of IMMX common stock through Mesa Verde Venture Partners III, LP, where he serves as Managing Director with voting and dispositive power over these shares.

When do Carey Ng's IMMX stock options expire?

The stock options granted to Carey Ng expire on June 20, 2035, ten years after the grant date.
Immix Biopharma Inc

NASDAQ:IMMX

IMMX Rankings

IMMX Latest News

IMMX Latest SEC Filings

IMMX Stock Data

62.45M
16.62M
40.1%
12.19%
1.4%
Biotechnology
Pharmaceutical Preparations
Link
United States
LOS ANGELES